vTv Therapeutics Has $77.2 Million In Cash As Diabetes Trial Heads Toward Results
The quarterly shareholder loss widened to $11.6 million, while management expects cash to cover operations beyond the trial readout.
vTv Therapeutics, which develops experimental oral medicines for diabetes and other chronic diseases, reported a $11.6 million loss attributable to shareholders Thursday, up from $8.7 million a year earlier. The company had $77.2 million in cash at September 30 and expects that money to fund operations well beyond the anticipated mid-2027 results of its late-stage type 1 diabetes trial.
Higher Costs, Lower Loss Per Share
Research spending reached $7.5 million in the third quarter, compared with $7.0 million a year earlier, primarily because of continued investment in the cadisegliatin trial. Administrative costs increased to $4.9 million from $3.7 million, principally because stock-based pay and payroll expenses rose.
The larger shareholder loss came with a smaller per-share loss: $0.94, versus $1.08 a year earlier. The weighted-average share count was 12,423,917, compared with 8,055,940. Interest income from money-market accounts rose to $0.7 million from $0.4 million.
Cash was down from $88.9 million at December 31, 2025. The first nine months nevertheless looked different from the quarter: vTv reported $36.839 million in revenue and a $540,000 shareholder loss, compared with no revenue and a $19.836 million shareholder loss in the same period of 2025.
166 Participants, Results Expected Mid-2027
Cadisegliatin is being tested as a pill added to insulin, rather than a replacement for it. The experimental medicine acts on a liver enzyme involved in glucose processing; its safety and effectiveness have not been established, although it has FDA Breakthrough Therapy designation.
The company announced in October that its late-stage trial had completed enrollment, with 166 participants randomized. Adults using insulin injections or an insulin pump, together with continuous glucose monitoring, receive placebo or 800 milligrams of cadisegliatin once or twice daily over six months.
The main goal is to measure level 2 and level 3 episodes of hypoglycemia, or low blood sugar. Other measures include blood-sugar control, time within the target glucose range and diabetic ketoacidosis.
Paul Sekhri, vTv's chairman, president and chief executive officer, said, “we look forward to reporting topline results in mid 2027.”
A separate pilot study examines cadisegliatin in people using hybrid closed-loop insulin delivery systems. vTv announced the first participant's randomization on October 27; the study is intended to help shape future late-stage research in that population.
Low Blood Sugar And Another Candidate
The company also presented research on the burden that persists among users of automated insulin delivery systems. At the Breakthrough T1D Clinical & Research Congress in Philadelphia on October 10, vTv Chief Medical Officer Thomas Strack presented a company-commissioned online survey conducted by dQ&A Market Research.
The survey covered 674 adults with type 1 diabetes, including 429 automated-system users. After adjusting for overlapping burdens and weighting for A1C, an estimated approximately 54% of those users experienced at least one of four dimensions of hypoglycemia-related burden.
An October 20 virtual discussion featured diabetes experts Schafer Boeder of Paradigm Clinical Research and the University of California San Diego, Klara Klein of the University of North Carolina at Chapel Hill School of Medicine, and cellist and diabetes advocate Alisa Weilerstein.
Beyond diabetes, the FDA granted Orphan Drug Designation to HPPD on October 6. The oral sickle cell disease candidate increased fetal hemoglobin and reduced oxidative stress and sickled red blood cells in mouse studies at Augusta University. Those are preclinical findings, not established benefits in people. vTv says the designation supports partnering discussions while cadisegliatin remains its priority.
The next major clinical milestone remains the expected mid-2027 diabetes trial readout—the event management uses to frame its cash forecast.
Sources
- 8-K Filing — vTv Therapeutics Inc. (VTVT) — SEC EDGAR
- Exhibit vtvt-20260930xexx991pressr.htm — vTv Therapeutics Inc. 8-K exhibit — SEC EDGAR
- vTv Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com